Suppliers and packagers for generic pharmaceutical drug: avanafil

avanafil

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hetero Labs Ltd V	AVANAFIL	avanafil	TABLET;ORAL	209266	ANDA	Camber Pharmaceuticals, Inc.	31722-440-01	100 TABLET in 1 BOTTLE (31722-440-01)	2024-06-14
Hetero Labs Ltd V	AVANAFIL	avanafil	TABLET;ORAL	209266	ANDA	Camber Pharmaceuticals, Inc.	31722-440-30	30 TABLET in 1 BOTTLE (31722-440-30)	2024-06-14
Hetero Labs Ltd V	AVANAFIL	avanafil	TABLET;ORAL	209266	ANDA	Camber Pharmaceuticals, Inc.	31722-441-01	100 TABLET in 1 BOTTLE (31722-441-01)	2024-06-14

Avanafil Drug Component Suppliers

Last updated: February 19, 2026

Avanafil, a phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction, relies on a specific set of chemical precursors and manufacturing capabilities for its synthesis. The primary active pharmaceutical ingredient (API) is avanafil itself, and its production involves several key intermediates. Sourcing for these components is critical for ensuring consistent supply, managing costs, and maintaining quality control in avanafil manufacturing.

What are the Key Chemical Intermediates for Avanafil Synthesis?

The synthesis of avanafil involves a multi-step chemical process that requires specific organic compounds. The main intermediates identified through patent literature and chemical synthesis pathways include:

• 5-amino-3-(4-chlorophenyl)-1-(3,5-dimethylphenyl)-1H-pyrazole-4-carboxamide: This is a core pyrazole derivative that forms a significant portion of the avanafil molecule. Its synthesis is a crucial early step.
• Ethoxymethylenemalononitrile: This reagent is used to build the pyrazole ring system.
• 4-chloroaniline: A common chemical building block, it provides the chlorophenyl moiety.
• 3,5-dimethylaniline: This provides the dimethylphenyl substituent.
• Sulfonyl chlorides or related sulfonating agents: These are used to introduce the sulfonyl group characteristic of avanafil's structure.

The precise sequence and specific reagents can vary slightly depending on the patented synthesis route, but these represent the foundational chemical structures.

Who are the Primary Suppliers of Avanafil API and Key Intermediates?

The supply chain for avanafil API and its critical intermediates is concentrated among specialized chemical manufacturers, often operating in the contract development and manufacturing organization (CDMO) space, particularly in regions with established pharmaceutical chemical industries like China and India.

Specific companies identified as potential or confirmed suppliers for avanafil API or its precursor intermediates include:

• Indian Manufacturers: India is a dominant force in generic API production. Several Indian chemical companies possess the expertise and regulatory compliance to produce avanafil and its intermediates. These often include companies involved in custom synthesis and API manufacturing. While specific client relationships are confidential, companies with broad portfolios of PDE5 inhibitors or heterocyclic chemistry expertise are likely involved.
• Chinese Manufacturers: China also represents a significant global supplier for pharmaceutical intermediates and APIs. Many Chinese chemical synthesis companies offer custom manufacturing services and have expertise in complex organic synthesis required for avanafil production. Similar to India, specific supplier names are often proprietary, but the country's manufacturing capacity is substantial.
• Specialty Chemical Companies: Beyond large-scale API producers, specialized chemical synthesis firms may supply specific, complex intermediates that require niche expertise or proprietary processes. These companies may not produce the final API but provide critical building blocks.

Direct sourcing information for avanafil is often proprietary due to competitive market dynamics and confidential supply agreements between API manufacturers and finished dosage form producers. However, market intelligence reports and trade databases often identify key players in the broader pharmaceutical intermediate market. For instance, companies specializing in the production of pyrazole derivatives or compounds with similar structural motifs would be strong candidates.

What are the Regulatory and Quality Control Requirements for Avanafil Suppliers?

Suppliers of avanafil API and its key intermediates must adhere to stringent regulatory and quality control standards to ensure the safety, efficacy, and consistency of the final drug product. These requirements are overseen by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and their equivalents in other jurisdictions.

Key requirements include:

• Good Manufacturing Practices (GMP): Suppliers must operate under current GMP guidelines. This encompasses rigorous control over manufacturing processes, facility management, personnel training, documentation, and quality assurance systems.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These comprehensive documents detail the chemistry, manufacturing, and controls (CMC) of the API, including specifications, analytical methods, stability data, and manufacturing site information.
• Impurity Profiling and Control: Suppliers must demonstrate robust control over impurities, including process-related impurities and degradation products. Comprehensive impurity profiles and validated analytical methods for their detection and quantification are essential.
• Batch-to-Batch Consistency: Strict process validation and in-process controls are required to ensure that each batch of API meets predetermined specifications for identity, purity, strength, and quality.
• Stability Testing: Suppliers must provide comprehensive stability data demonstrating that the API remains within its specifications under recommended storage conditions for its intended shelf life.
• Supply Chain Transparency and Traceability: Pharmaceutical companies demand transparency in their supply chains. Suppliers must be able to trace the origin of raw materials and demonstrate control over their own sourcing.
• Audits and Inspections: Pharmaceutical clients and regulatory authorities conduct regular audits and inspections of supplier facilities to verify compliance with GMP and other regulatory requirements.

The ability to meet these standards is a prerequisite for inclusion in the supply chain of any pharmaceutical product, including avanafil.

What are the Potential Challenges in Sourcing Avanafil Intermediates?

Sourcing critical intermediates for avanafil can present several challenges for pharmaceutical manufacturers. These challenges can impact production timelines, costs, and product quality.

• Supply Chain Disruptions: Geopolitical events, natural disasters, or localized manufacturing issues can disrupt the supply of key intermediates. Concentration of manufacturing in specific regions increases vulnerability.
• Quality Consistency: Ensuring consistent quality across different batches and from different suppliers is paramount. Variations in intermediate quality can lead to downstream manufacturing problems and affect the final API's purity.
• Price Volatility: The cost of raw materials and the complex synthesis involved can lead to price fluctuations for intermediates, impacting the overall cost of goods for avanafil.
• Intellectual Property (IP) and Patent Landscape: While avanafil itself may be off-patent in some markets, specific synthesis routes or novel intermediate production methods might still be protected by patents. Navigating this IP landscape is crucial.
• Lead Times: The production of complex chemical intermediates often involves significant lead times. Manufacturers must plan well in advance to secure sufficient quantities.
• Regulatory Hurdles: Changes in regulatory requirements or unexpected findings during regulatory reviews can impact the approved suppliers and manufacturing processes.
• Limited Supplier Pool: For highly specialized intermediates, the number of qualified suppliers may be limited, creating a bottleneck and increasing reliance on a few key partners.

Mitigating these challenges requires robust supply chain management, strong supplier relationships, dual sourcing strategies where feasible, and proactive engagement with regulatory requirements.

What is the Impact of the Avanafil Patent Expiration on Supplier Dynamics?

The expiration of key patents related to avanafil has a significant impact on the supplier landscape, primarily by opening the market to generic competition.

• Increased Demand for Generic API: As patents expire, generic drug manufacturers enter the market, leading to a substantial increase in demand for avanafil API and its precursor intermediates.
• New Entrant Suppliers: The increased market opportunity incentivizes new API manufacturers, particularly those in India and China, to develop and offer avanafil API and its intermediates. This expands the supplier pool.
• Price Pressure: The introduction of multiple generic competitors intensifies price competition. This pressure extends down the supply chain, forcing intermediate suppliers to optimize their costs and improve efficiency to remain competitive.
• Focus on Cost-Effective Synthesis: Generic manufacturers often seek out the most cost-effective synthesis routes. This can lead to a shift in demand towards suppliers who can offer intermediates produced via optimized, high-yield, and lower-cost processes.
• Regulatory Scrutiny of New Entrants: While the market opens, regulatory agencies maintain rigorous scrutiny of new API and intermediate suppliers, ensuring they meet GMP and quality standards. Successful entry requires significant investment in compliance.
• Shift in Buyer Power: The larger number of API suppliers can shift bargaining power towards generic drug manufacturers, who can then negotiate more favorable terms with intermediate suppliers.

The post-patent expiration period typically sees a dynamic market with evolving supplier relationships and a heightened focus on cost and efficiency.

Key Takeaways

• Avanafil synthesis requires specific pyrazole-based intermediates, notably 5-amino-3-(4-chlorophenyl)-1-(3,5-dimethylphenyl)-1H-pyrazole-4-carboxamide, and reagents like ethoxymethylenemalononitrile.
• Primary suppliers for avanafil API and key intermediates are predominantly located in India and China, operating as CDMOs and specialized chemical manufacturers.
• Suppliers must adhere to stringent GMP, DMF filing, and impurity control standards mandated by global regulatory bodies.
• Sourcing challenges include supply chain disruptions, quality consistency, price volatility, and IP considerations.
• Avanafil patent expirations drive increased demand for generic API, attract new suppliers, and intensify price competition throughout the supply chain.

---

FAQs

1. Are there any U.S.-based manufacturers of avanafil API or its key intermediates? While the majority of bulk API and intermediate manufacturing for pharmaceuticals, including avanafil, is concentrated in Asia, some U.S. companies may engage in custom synthesis for specific advanced intermediates or in the final stages of formulation. However, large-scale primary intermediate production is less common.

2. How can a pharmaceutical company vet a new supplier for avanafil intermediates? Vetting involves a multi-pronged approach including a thorough review of GMP certifications, recent audit reports (FDA, EMA, or client audits), facility inspections, assessment of their quality management system, evaluation of their impurity control strategies, and a review of their DMF or equivalent documentation.

3. What is the typical shelf life of avanafil API supplied by manufacturers? The typical shelf life of avanafil API, as stated in DMFs and determined by stability studies, generally ranges from 2 to 5 years when stored under recommended conditions. Specific expiry dates are batch-dependent.

4. Does the synthesis route for avanafil have any known environmental concerns that suppliers must address? Like many complex organic syntheses, avanafil production can involve the use of organic solvents and reagents. Responsible suppliers implement waste management protocols, solvent recovery systems, and strive for greener chemistry approaches to minimize environmental impact, addressing concerns related to solvent disposal and potential hazardous byproducts.

5. How does the regulatory status of a supplier's manufacturing site (e.g., FDA inspection history) affect its ability to supply avanafil components to the U.S. market? A positive FDA inspection history, or at least an absence of significant adverse findings, is critical. An FDA warning letter or import alert for a manufacturing site can prevent that site from supplying components used in drugs marketed in the U.S., effectively blocking their participation in the avanafil supply chain for that market.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practices. Retrieved from [FDA website on GMPs]. [2] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). Retrieved from [EMA website on GMPs]. [3] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from [FDA website on DMFs]. [4] PubChem. (n.d.). Avanafil. National Center for Biotechnology Information. Retrieved from [PubChem Database entry for Avanafil]. [5] Patent literature databases (e.g., Google Patents, Espacenet) for synthesis routes of avanafil. (Specific patent numbers would be cited if detailing a particular route, but as a general reference to available synthesis information).